

Specificity

Specifically recognizes the target-SN38.

Source

Monoclonal Anti-SN38 Antibody, Mouse IgG1 is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.

Isotype

Mouse IgG1 | Mouse Kappa

Conjugate

Unconjugated

Reactivity

Chemical

Immunogen

SN38-OVA

Application

Application	Recommended Usage
ELISA	0.1-8 ng/mL

Purification

Protein A purified / Protein G purified

Formulation

Lyophilized from 0.22 µm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.


This product is stable after storage at:

- 20°C to -70°C for 12 months in lyophilized state;
- 70°C for 3 months under sterile conditions after reconstitution.

Bioactivity-ELISA



Immobilized Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) at 1 µg/mL, add Sacituzumab Govitecam in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 µg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).




Immobilized Sacituzumab govitecam at 1 µg/mL (100 µL/well) can bind Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) with a linear range of 0.12-0.98 ng/mL (Routinely tested).

Cross Verification



Monoclonal Anti-SN38 Antibody, Mouse IgG1

Catalog # SN8-M685



ELISA binding of Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively.

The coating antibody was Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685), used at 1 µg/mL concentration. The primary antibody were different payload conjugated antibodies, including Trastuzumab Deruxtecan, Sacituzumab Govitecam, Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 µg/mL concentration. The secondary antibody was Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specific (min X Bov, Hrs, Ms Sr Prot) (Jackson, Cat. No. 109-035-098) used at 1:12000 concentration.

Monoclonal Anti-SN38 Antibody, Mouse IgG1 (Cat. No. SN8-M685) is specific to Sacituzumab Govitecam and has no cross-reactivity with Trastuzumab Deruxtecan, Trastuzumab MMAE and Trastuzumab-DM1 (Routinely tested).

Background

The 7-ethyl-10-hydroxycamptothecin (SN-38) is a topoisomerase I inhibitor (chemotherapeutic agent) used in cancer therapy. In a comparative study of SN-38 with a potent chemotherapeutic prodrug, irinotecan (CPT-11), SN-38 was found to be 1000-fold more cytotoxic against colorectal cancer cells as compared to irinotecan.

